Phase II Trial Utilizing Idarubicin in Combination With High Dose Ara-C [cytarabine] for Induction Therapy for Adult Acute Myelogenous Leukemia (AML).
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cytarabine (Primary) ; Idarubicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 06 Feb 2017 Biomarkers information updated
- 26 Nov 2012 Planned end date changed from 1 Aug 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 16 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.